CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market pri ...

Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.37 per share, which would represent a year-over-year decline of 39.8%. Our most recent consensus estimate is calling for quarterly revenue of $8.39 million, down 88.02% from the year-ago period. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Z ...

Summary of CRISPR Therapeutics AG Conference Call Company Overview - **Company**: CRISPR Therapeutics AG (NASDAQ: CRSP) - **Date**: June 11, 2024 - **Participants**: Sam Kulkarni (CEO), Salveen Richter (Goldman Sachs) Key Points Industry and Company Focus - CRISPR Therapeutics is focusing on multiple verticals: cancer, ex-vivo non-cancer, regenerative medicine, and in vivo gene editing [2][3][5] - The company aims to balance its portfolio between rare and common diseases, believing CRISPR technology can impact both equally [2][3] Pipeline and R&D Strategy - The company has an approved drug, Casgevy, for sickle cell disease and thalassemia, marking a significant milestone [3] - CRISPR is leveraging its expertise in cell handling and technologies to develop best-in-class CAR-T therapies for cancer [3] - Regenerative medicine is viewed as an under-invested area with potential for significant impact on longevity and organ replacement [4] - In vivo gene editing is a growing focus, with plans for multiple programs targeting various organs [5] Innovation and Adaptation - CRISPR Therapeutics is committed to staying at the forefront of gene editing technology, adapting to innovations in the field [7][8] - The company has established a group called CRISPR X to explore next-generation applications of CRISPR technology [8] Delivery Technology - The company is shifting focus from viral delivery vehicles to lipid nanoparticles (LMPs) due to their safety and degradability [11][12] - LMPs are being explored for various organ systems, with ongoing challenges in non-liver applications [13] Commercial Portfolio and Casgevy Launch - The launch of Casgevy is seen as a significant opportunity, with high demand and supportive reimbursement from healthcare systems [15][16][17] - The company anticipates a long-term growth trajectory for Casgevy, differing from typical pharmaceutical launches [18] Reimbursement Landscape - The U.S. market has normalized its approach to rare disease pricing, with a better understanding of cell and gene therapies [20] - European markets are still adapting, with varying processes across countries [21] Patient Preferences - Patients show a preference for CRISPR-based therapies over traditional gene therapies when both options are available [24][25] Future Developments - The company is working on improving the preconditioning regimen for Casgevy to expand the patient population [26][27] - In vivo editing for hematopoietic cells is a long-term goal, with ongoing research into targeted LMPs [29] Cardiovascular Disease Trials - Upcoming data on cardiovascular disease trials is expected to provide insights into gene editing's effectiveness in reducing risk factors [31][32] Autoimmune Vertical - CRISPR is exploring opportunities in autoimmune diseases, particularly lupus, with a focus on CD19-directed cell therapies [34][36] - The company is well-positioned to compete in this space due to its unique approach and manufacturing capabilities [38] Oncology Portfolio - The oncology vertical remains a priority, with upcoming data expected to inform future strategies [41][44] - The company is advancing multiple CAR-T programs, including CTX-110 and CTX-112, targeting CD19 and CD70 [46] Regenerative Medicine - Regenerative medicine efforts are significant, particularly in developing stealth cells for Type 1 diabetes and other organ systems [48][50] Conclusion CRISPR Therapeutics AG is strategically positioned in the gene editing landscape, focusing on a diverse pipeline that includes cancer therapies, regenerative medicine, and autoimmune diseases. The company is adapting to technological advancements and market dynamics while maintaining a strong emphasis on patient needs and innovative delivery methods.

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this company have returned +7.8% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has gained 1.2% over this period. Now the key question is: Where could the stock be headed in the near ...

A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP) . Shares have added about 12% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q1 Loss Narrower-Than-Expected, Sa ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Good morning. My name is Maury Raycroft and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the CEO of CRISPR Therapeutics Sam Kulkarni. Thanks so much for joining us today, Sam. We're going to do fireside chat format. So m ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Samarth Kulkarni Yes, for those who are not familiar with CASGEVY, this is a product where it's an ex vivo cell therapy product. We take patient cells, edit them using CRISPR/Cas9 to produce fetal hemoglobin and the elevated fetal hemoglobin makes up for the deficiency or defectiveness of the adult beta globin. And this was an approach that ...

In keeping with Cathie Wood's style, these picks are riskier than average. Via her ARK Innovation ETF (ARKK 1.25%), portfolio manager Cathie Wood makes a lot of biotech bets, often on companies that are at the cutting edge of innovation in science and technology. Businesses like that tend to have volatile and temperamental stocks, though investors are lured back time and time again because they offer the possibility of big returns in exchange for significant risks. Does it make sense to invest in these stoc ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this company have returned +3.5%, compared to the Zacks S&P 500 composite's +4.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 5%. The key question now is: What could be the stock's future direc ...

Core Viewpoint - CRISPR Therapeutics presents multiple investment opportunities through its commercialized product, a robust pipeline, and strong financial position [1][2] Group 1: Commercialized Product - Casgevy, CRISPR's first commercialized gene therapy for sickle cell disease and beta thalassemia, is in global rollout with approvals in the U.S., E.U., and U.K. [3] - Currently, there are 25 authorized treatment centers worldwide, with more expected to open, leading to increased patient eligibility and sales [4] - Improvements in the manufacturing process could expand the addressable market by making treatment less burdensome for patients [6] Group 2: Pipeline Programs - The R&D pipeline includes clinical-stage programs targeting large markets, such as the CTX 320 program for atherosclerotic cardiovascular disease, projected to reach $195.8 billion by 2030 [7] - Another program, CTX 310, aims to treat various dyslipidemias, with potential applications for general cholesterol reduction [8] - The diverse pipeline increases the likelihood of successful drug development, providing a bullish outlook for the future [9] Group 3: Financial Position - CRISPR Therapeutics has a strong balance sheet with approximately $2.1 billion in cash and equivalents, zero long-term debt, and minimal capital lease obligations [10] - With trailing-12-month operating expenses of $433.6 million, the company has ample financial resources and can secure additional funding if necessary [11] - The lack of financial pressure allows the company to invest strategically in growth opportunities [12]